| Generic and LCM products pipeline |
Pre-clinical |
Clinical Batch |
Phase I |
Registration |
Market authorization |
Launch |
| Antihistaminic therapy: Cetirizine 10 mg/ml Oral solution (drops) |
|
|
|
|
Granted in March 2007 |
|
| Antiviral therapy:
Valacyclovir 500 mg and 1 g
Orodispersible/dispersible tablet - LCM ODTx® |
|
|
|
Q2/2012 |
|
|
| Antiviral therapy: Valacyclovir 375 mg and 750 mg
MR tablet - LCM Microgix® |
|
|
|
Q4/2011 |
|
|
| Brain disorder therapy: Risperidone 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg Orodispersible/dispersible tablet - ODTx® |
|
|
|
|
Q3/2011 |
|
| Cardiovascular therapy: Celiprolol 200 mg Coated tablet |
|
|
|
|
Granted |
|
| Dermatology therapy: Ketoconazole Gel 2% Tube and stick-pack |
|
|
|
|
|
Feb. 2008 |
| Gastro-enterology therapy - Antiacid + PPI: Esomeprazole 20 mg and 40 mg IR Orodispersible delayed tablet - LCM Microgix® |
|
|
|
Q3/2012 |
|
|
| Gastro-enterology therapy - Antiacid + PPI: Lansoprazole 15 mg and 30 mg IR Orodispersible delayed tablet - LCM Microgix® |
|
|
|
Q3/2012 |
|
|
| Gastro-enterology therapy - Antiacid + PPI: Pantoprazole 15 mg and 30 mg IR Orodispersible delayed tablet - LCM Microgix® |
|
|
|
Q4/2012 |
|
|
| Gastro-enterology therapy: Domperidone 10 mg Orodispersible tablet - ODTx® + Patent |
|
|
|
|
Granted in Dec. 2006 |
|
| Gastro-enterology therapy: Lansoprazole 15 mg and 3 mg Delayed orodispersible tablet - Microgix® |
|
|
|
Q2/2012 |
|
|
| Metabolism therapy - antialzheimer application: Donepezil 5 mg and 10 mg Orodispersible tablet - ODTx® |
|
|
|
|
Q2/2011 |
|
| Metabolism therapy - Antidiabetic oral application: Metformine 500 mg, 850 mg and 1 g Orodispersible/dispersible tablet - LCM ODTx®
Metformine 500mg, 850mg, 1000mg - Exclusive licence for European Territory |
|
|
|
|
|
Nov. 2007 |
| Metabolism therapy - Association of two anti-Alzheimer agents: Donepezil/Memantin 10 mg/10 mg
Orodispersible/dispersible tablet - LCM ODTx® |
|
|
|
Q4/2011 |
|
|
| Metabolism therapy - Hypolipidemic application:
Fenofibrate 145 mg
MR Tablet - LCM Microgix® + Patent |
|
|
|
Q2/2012 |
|
|
| Metabolism therapy - Hypolipidemic application:
Fenofibrate 160 mg
Modified release Tablet - Patent |
|
|
|
|
Granted in Feb. 2006 |
|
| Metabolism therapy - Hypolipidemic application:
Fenofibrate 200 mg
Tablet - Patent |
|
|
|
|
Granted in Feb. 2003 |
|
| Metabolism therapy - Hypolipidemic application:
Fenofibrate 67 mg
Tablet - Patent |
|
|
|
|
Feb. 2003 |
|
| Opioid addiction therapy: Buprenorphine/naloxone 2 mg/0.5 mg and 8 mg/2 mg Orodispersible tablet - ODTx® + Patent |
|
|
|
Q3/2012 |
|
|
| Osteoporosis therapy - Pain relief application: Chondroitin/Glucosamin 400 mg/1250 mg Orodispersible/dispersible tablet - LCM ODTx® |
|
|
|
Q2/2012 |
|
|
| Osteoporosis therapy : Chondroitin 400 mg and 500 mg Orodispersible/dispersible tablet - LCM ODTx® |
|
|
|
Q2/2012 |
|
|
| Osteoporosis therapy: Risedronate 35 mg + Ca 2 + Vit. D3 Coated tablet |
|
|
|
|
Q2/2012 |
|
| Osteoporosis therapy: Risedronate 35 mg Coated tablet |
|
|
|
|
Q4/2011 |
|
| Pain disease therapy: Acetaminophen 1g Tablet - Minextab® + Patent |
|
|
|
|
|
March 2004 |
| Supplement therapy - Vitamin application: Calcium/Cholecalceferol (Vit. D3) 1000 mg/800 ui
Chewable dispersible tablet |
|
|
|
Q4/2011 |
|
|
